2. PI3K/Akt/mTOR Stem Cell/Wnt Autophagy
  3. GSK-3 Wnt β-catenin Autophagy
  4. Laduviglusib

Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

For research use only. We do not sell to patients.

Laduviglusib

Laduviglusib Chemical Structure

CAS No. : 252917-06-9

Size Price Stock Quantity
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Laduviglusib Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Laduviglusib

View All GSK-3 Isoform Specific Products:

View All Isoforms
GSK-3 GSK-3α GSK-3β

View All Wnt Isoform Specific Products:

View All Isoforms
Wnt1 Wnt3 Wnt5 Wnt7

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

IC50 & Target[1]

GSK-3β

6.7 nM (IC50)

GSK-3α

10 nM (IC50)

CDC2

8800 nM (IC50)

In Vitro

Laduviglusib (GMP) (20 μM, 21 days) transdifferentiates mouse fibroblasts to neurons (determined by increased number of TAUEGFP-/TUJ1-positive neuronal cells)[1].
Laduviglusib (GMP) (3-5 μM, 2 days) induces somatic cells differentiation of pluripotent stem (PS) cells (the detailed method refers to the reference)[2].
Laduviglusib (GMP) (12 μM, 5 days) converts human fibroblasts (HFF) into functional cardiomyocytes[3].
Laduviglusib (GMP) (3 μM, 4 days, hESCs) activates the canonical WNT signaling pathway, confirmed by β-catenin translocation into the nucleus[4].
Laduviglusib (GMP) (in MEFs expressing MyoD) enhances the marked increase in the number of proliferative cells led by RepSox (GMP) (HY-13012G) together with Forskolin (HY-15371)[5].
Laduviglusib (GMP) (5 μM, 1 day) can be used to generate islets (hCiPSC-islets) from human chemically induced pluripotent stem cells (hCiPSC)[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Laduviglusib Related Antibodies
Molecular Weight

465.34

Formula

C22H18Cl2N8
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

N#CC1=CC=C(N=C1)NCCNC2=NC=C(C(C3=CC=C(Cl)C=C3Cl)=N2)C4=NC=C(N4)C
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (53.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1490 mL 10.7448 mL 21.4897 mL
5 mM 0.4298 mL 2.1490 mL 4.2979 mL
View the Complete Stock Solution Preparation Table

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1490 mL 10.7448 mL 21.4897 mL 53.7242 mL
5 mM 0.4298 mL 2.1490 mL 4.2979 mL 10.7448 mL
10 mM 0.2149 mL 1.0745 mL 2.1490 mL 5.3724 mL
15 mM 0.1433 mL 0.7163 mL 1.4326 mL 3.5816 mL
20 mM 0.1074 mL 0.5372 mL 1.0745 mL 2.6862 mL
25 mM 0.0860 mL 0.4298 mL 0.8596 mL 2.1490 mL
30 mM 0.0716 mL 0.3582 mL 0.7163 mL 1.7908 mL
40 mM 0.0537 mL 0.2686 mL 0.5372 mL 1.3431 mL
50 mM 0.0430 mL 0.2149 mL 0.4298 mL 1.0745 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Laduviglusib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Laduviglusib (GMP)252917-06-9CHIR-99021 (GMP)CT99021 (GMP)GSK-3Wntβ-cateninAutophagyGlycogen synthase kinase-3Glycogen synthase kinase 3Beta cateninGMPWnt/β-cateninES cellES-D3 celladipogenesisGI injuryreprogramPSCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Laduviglusib
Cat. No.:
HY-10182G
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Portuguese - PT (480 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.